TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22902977

Group type: EXPERIMENTAL
Intervention: Self-monitoring diaries in a weight loss program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no self-monitoring diaries)
Number of subjects: 50
Study: 19765700

Group type: EXPERIMENTAL
Intervention: PCOS Normal-Weight (NW)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PCOS Obese (Ob)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Normal-Weight (NW)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Obese (Ob)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PCOS
Number of subjects: 43
Study: 18765046

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 80
Study: 16186467

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs)
Number of subjects: 10739
Study: 12673431

Group type: EXPERIMENTAL
Intervention: Revised CONSORT statement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Checklist and flow diagram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow diagram
Number of subjects: 0
Study: 10621528

Group type: EXPERIMENTAL
Intervention: Oral acyclovir as prophylaxis against recurrent stromal keratitis
Number of subjects: 0
Study: 8659620

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment of residual symptoms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard clinical management
Number of subjects: 40
Study: 29150861

Group type: EXPERIMENTAL
Intervention: HypoAware intervention (blended psycho-educational intervention)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study: 27311902

Group type: EXPERIMENTAL
Intervention: Referral to electronic brief intervention (eBI)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Face-to-face advice
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Referral to eBI
Number of subjects: 746
Study: 23824500

Group type: EXPERIMENTAL
Intervention: Bipolar diagnosed participants
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: PTSD diagnosed participants
Number of subjects: 190

Group type: COMPARATOR
Intervention: ADHD diagnosed participants
Number of subjects: 190

Group type: COMPARATOR
Intervention: Matched comparison samples
Number of subjects: 190
Study: 22626491

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 593
Study: 21169002

Group type: EXPERIMENTAL
Intervention: Montelukast (CysLT receptor 1 antagonist)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 18022545

Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15598669

Group type: EXPERIMENTAL
Intervention: ORAL
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DEPO
Number of subjects: 36

Group type: COMPARATOR
Intervention: EU-OV
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HAPT (all groups)
Number of subjects: 36
Study: 11948850

Group type: EXPERIMENTAL
Intervention: Nevirapina (test formulation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Viramune (reference formulation)
Number of subjects: 25
Study: 10407237

Group type: EXPERIMENTAL
Intervention: Continual low dose corticosteroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8534439

Group type: EXPERIMENTAL
Intervention: Perkins tonometer
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Schiotz tonometer
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tonopen tonometer
Number of subjects: 73

Group type: COMPARATOR
Intervention: Goldmann Applanation tonometer (gold standard)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Follow-up assessments (funduscopy, gonioscopy, repeat measurement of intraocular pressure, visual field assessment)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: General practice patients
Number of subjects: 73
Study: 2076222

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (1100 ppm F)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15
Study: 511419

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 0.2 mg/kg body weight pirenzepine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Solvent injection (control)
Number of subjects: 16
Study: 31408791

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 60

Group type: COMPARATOR
Intervention: cTBS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study: 27613719

Group type: EXPERIMENTAL
Intervention: Group-based step aerobics exercise (EG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 48
Study: 26350550

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted gastrectomy (LAG)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional open gastrectomy (OG)
Number of subjects: 270
Study: 24156306

Group type: COMPARATOR
Intervention: Protocol A (12 mmol/l citrate, HCO3- 32 mmol/l replacement fluid)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protocol B (18 mmol/l citrate with phosphate-containing dialysate/replacement fluid, HCO3- 30 mmol/l, Phosphate 1.2)
Number of subjects: 40
Study: 21335007

Group type: EXPERIMENTAL
Intervention: PegIFN therapy
Number of subjects: 813

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Baseline stainable iron in hepatocytes and portal tract cells
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Iron in triads at baseline
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Stainable iron in hepatocytes
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Stainable iron in portal stromal cells
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Serum iron and TIBC
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Serum ferritin
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: HFE genetic variations
Number of subjects: 813
Study: 19352198

Group type: EXPERIMENTAL
Intervention: Pregabalin 300-450 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (alprazolam 1.5 mg/day; lorazepam 6 mg/day)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 16723311

Group type: EXPERIMENTAL
Intervention: Formulation 1 containing 250 mg vitamin C
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Formulation 2 containing 250 mg vitamin C
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Formulation 3 containing 250 mg vitamin C
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 15167335

Group type: COMPARATOR
Intervention: Hooks in claw configuration in both the thoracic and lumbar spine (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hooks in thoracic vertebrae and pedicle screws in lumbar vertebrae (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study: 10902623

Group type: EXPERIMENTAL
Intervention: Condoms available in rooms
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Directly handing condoms to couples
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Health‐education material present
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Condoms on request
Number of subjects: 6463
Study: 9315597

Group type: EXPERIMENTAL
Intervention: Low-dose pravastatin combined with low-dose cholestyramine
Number of subjects: 59

Group type: COMPARATOR
Intervention: High-dose pravastatin monotherapy
Number of subjects: 59
Study: 10148847

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HCC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-coated circuits (NCC)
Number of subjects: 24
Study: 3518638

Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 20
Study: 29579195

Group type: EXPERIMENTAL
Intervention: MST3 (3 rounds of mass screening and treatment)
Number of subjects: 1870

Group type: EXPERIMENTAL
Intervention: MST2 (2 rounds of mass screening and treatment)
Number of subjects: 1870

Group type: COMPARATOR
Intervention: MST0 (no mass screening and treatment)
Number of subjects: 1870
Study: 27076772

Group type: EXPERIMENTAL
Intervention: Active care (6 mo colonoscopy and drug intensification for endoscopic recurrence)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (drug therapy without early endoscopy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colonoscopy at 18 mo and faecal calprotectin (FC) measurement
Number of subjects: 60
Study: 25420889

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LS) 30mg once daily for 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lansoprazole (LS) 30mg once daily for 1 week followed by Ecabet Sodium (ES) 1500mg twice daily for 3 weeks
Number of subjects: 90
Study: 23539933

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 34
Study: 20723034

Group type: EXPERIMENTAL
Intervention: Terutroban 1 mg day(-1)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Terutroban 2.5 mg day(-1)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Terutroban 5 mg day(-1)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Terutroban 10 mg day(-1)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Terutroban 30 mg day(-1)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Aspirin 75 mg day(-1)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 18942055

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 89

Group type: COMPARATOR
Intervention: Anterior 180 degrees partial fundoplication
Number of subjects: 89
Study: 15892271

Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) plus chemotherapy (CT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Chemotherapy (CT) only
Number of subjects: 65
Study: 12322846

Group type: EXPERIMENTAL
Intervention: Enaril 5 mg tablets
Number of subjects: 14
Study: 10426610

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 microg tablet for at least four hours)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Vaginal gemeprost (1.0 mg vaginal suppository for at least three hours)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 199

Group type: COMPARATOR
Intervention: Vaginal gemeprost
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 199
Study: 7897139

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy or implantable cardioverter‐defibrillator therapy
Number of subjects: 0
Study: 2258063

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) with bacillus Calmette-Guerin (BCG)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) without bacillus Calmette-Guerin (BCG)
Number of subjects: 411
Study: 6263139

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions
Number of subjects: 46
Study: 30888737

Group type: EXPERIMENTAL
Intervention: CNTX‐4975 0.5 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: CNTX‐4975 1.0 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 29485309

Group type: EXPERIMENTAL
Intervention: Unilateral isokinetic resistance training of the knee extensors for 4 weeks
Number of subjects: 42
Study: 28984010

Group type: EXPERIMENTAL
Intervention: rhFVIIa 25 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhFVIIa 75 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhFVIIa 225 μg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rhFVIIa (all doses)
Number of subjects: 30
Study: 25927288

Group type: EXPERIMENTAL
Intervention: Single-limb high-repetitive resistance training with elastic bands, three times/week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-limb high-repetitive resistance training with elastic bands, three times/week for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-limb high-repetitive resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-limb high-repetitive resistance training
Number of subjects: 0
Study: 23489513

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic ureterolithotomy (LUL)
Number of subjects: 80
Study: 21472665

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (optimal diet therapy, sulfonylurea and/or insulin)
Number of subjects: 66
Study: 18604552

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonography in 400 patients (Group A) to identify arterial abnormalities associated with nonrecurrent ILN.
Number of subjects: 750

Group type: COMPARATOR
Intervention: No preoperative ultrasonography in 350 patients (Group B).
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonography in Group A.
Number of subjects: 750

Group type: COMPARATOR
Intervention: No preoperative ultrasonography in Group B.
Number of subjects: 750
Study: 16607061

Group type: EXPERIMENTAL
Intervention: Resin-based dentin sealer applied following manufacturer's recommendations
Number of subjects: 62

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 62
Study: 12518133

Group type: EXPERIMENTAL
Intervention: Second-look endoscopy with retreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 0
Study: 11273919

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl continuous infusion (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam infusion (Group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 45
Study: 9298429

Group type: EXPERIMENTAL
Intervention: Primarily noradrenergic reuptake inhibitor (desipramine)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) (sertraline or paroxetine)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Combined serotonin and norepinephrine reuptake inhibitor (SNRI) (venlafaxine)
Number of subjects: 158
Study: 8420442

Group type: EXPERIMENTAL
Intervention: Fosinopril (10 mg initial oral daily dose, then 20 mg once a day during open-label phase)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fosinopril (during extended open-label phase)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3521428

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 40
Study: 30118997

Group type: EXPERIMENTAL
Intervention: Genu Varum deformity (GVD) group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy group (without GVD)
Number of subjects: 44
Study: 26696613

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 4187

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4187
Study: 24819566

Group type: EXPERIMENTAL
Intervention: Darbepoetin (10 μg/kg, 1×/week subcutaneously)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Erythropoietin (400 U/kg, 3×/week subcutaneously)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (sham dosing 3×/week)
Number of subjects: 102
Study: 22535517

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20536518

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) <7.0%
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Glycated haemoglobin (HbA1c) <8.0%
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Use of aspirin
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors or ARBs
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Use of statins
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Use of statins in LDL >3.4 mmol/l
Number of subjects: 1153
Study: 18395397

Group type: EXPERIMENTAL
Intervention: Chronic Angina Self-Management Program (CASMP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wait-list usual care (control)
Number of subjects: 130
Study: 15677610

Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12924802

Group type: EXPERIMENTAL
Intervention: Elastic knee sleeve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (acetaminophen, NSAIDs, and education)
Number of subjects: 0
Study: 10640258

Group type: EXPERIMENTAL
Intervention: 5 mg zolmitriptan
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: 2.5 mg zolmitriptan
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (2.5 mg or 5 mg)
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg)
Number of subjects: 2499
Study: 9552521

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with a postangioplasty diameter stenosis less than 30%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent implantation
Number of subjects: 0
Study: 2669067

Group type: EXPERIMENTAL
Intervention: APD (300 mg/day orally)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study: 71972

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flurbiprofen 150 mg daily plus 3 g aspirin daily
Number of subjects: 15
Study: 29239988

Group type: EXPERIMENTAL
Intervention: With boards (WBs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Without boards (WOBs)
Number of subjects: 11
Study: 31652875

Group type: EXPERIMENTAL
Intervention: Combined supplementation with glycine and tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycine and tryptophan mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 0
Study: 29200944

Group type: EXPERIMENTAL
Intervention: Therapeutic cervical medial branch blocks (with or without steroids)
Number of subjects: 120
Study: 26091193

Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg b.i.d.
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg b.i.d.
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Asenapine (OLE phase)
Number of subjects: 306
Study: 24121097

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment for insomnia with weekly email support
Number of subjects: 262

Group type: COMPARATOR
Intervention: Internet-delivered cognitive behavioral treatment for insomnia without support
Number of subjects: 262
Study: 22111354

Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural ropivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 19812445

Group type: EXPERIMENTAL
Intervention: 300 mg maraviroc
Number of subjects: 24
Study: 22240547

Group type: EXPERIMENTAL
Intervention: Complex Training (CT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 15593395

Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Duration of disease
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Biochemical parameters
Number of subjects: 72
Study: 12730746

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 1 mg risedronate
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 2.5 mg risedronate
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Risedronate (1-5 mg doses)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Risedronate (up to 5 mg)
Number of subjects: 211
Study: 9690751

Group type: EXPERIMENTAL
Intervention: Mono test
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Tine test
Number of subjects: 875

Group type: COMPARATOR
Intervention: Mantoux test
Number of subjects: 875
Study: 8078010

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2680843

Group type: EXPERIMENTAL
Intervention: RS 86 (cholinergic agent)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline EEG-sleep parameters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RS 86
Number of subjects: 50

Group type: COMPARATOR
Intervention: REM sleep density
Number of subjects: 50

Group type: COMPARATOR
Intervention: Shortened REM latencies
Number of subjects: 50
Study: 607594

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass
Number of subjects: 38
Study: 29281749

Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalysis (MIP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Child Health Center care
Number of subjects: 33
Study: 27737690

Group type: COMPARATOR
Intervention: Conventional lung‐protective MV
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Conventional lung‐protective MV with NAVA
Number of subjects: 306
Study: 25331469

Group type: EXPERIMENTAL
Intervention: Ropivacaine local infiltration (0.5% ropivacaine, 40 ml, n = 22)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sodium chloride local infiltration (0.9% sodium chloride, 40 ml, n = 20)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no analgesic, n = 19)
Number of subjects: 61
Study: 22779759

Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 97